SMS Lifesciences India Ltd's Q4FY25 Quarter Results
- 30 May 2025
Result Summary
- SMS Lifesciences India Ltd reported a 9.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 39.5%.
- Its expenses for the quarter were up by 9.6% QoQ and 28.8% YoY.
- The net profit increased 33.1% QoQ and increased 206.6% YoY.
- The earnings per share (EPS) of SMS Lifesciences India Ltd stood at 19.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 92.35 | 84.66 | 66.19 | 9.1% | 39.5% |
Total Expenses | 85.25 | 77.75 | 66.17 | 9.6% | 28.8% |
Profit Before Tax | 7.10 | 6.92 | 2.37 | 2.6% | 199.6% |
Tax | 0.63 | 2.06 | 0.25 | -69.4% | 152.0% |
Profit After Tax | 6.47 | 4.86 | 2.11 | 33.1% | 206.6% |
Earnings Per Share | 19.50 | 18.10 | 5.70 | 7.7% | 242.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
SMS Lifesciences India Ltd operates within the pharmaceutical industry, focusing primarily on the manufacturing and sale of active pharmaceutical ingredients (APIs). The company is known for its expertise in the development and production of a wide range of APIs, catering to various therapeutic categories. SMS Lifesciences has established itself as a key player in the pharmaceutical sector, with a commitment to quality and innovation in its product offerings. The company aims to expand its global footprint by exploring new market opportunities and enhancing its existing product portfolio. There is no recent major development available for SMS Lifesciences India Ltd based on the information provided.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), SMS Lifesciences India Ltd reported a total income of ₹92.35 crores, reflecting a significant increase from the previous quarter (Q3FY25) and the same quarter in the previous fiscal year (Q4FY24). The quarter-over-quarter (QoQ) growth in total income was 9.1%, while the year-over-year (YoY) growth was an impressive 39.5%. This substantial rise in revenue indicates a robust performance in sales and operational effectiveness within the period analyzed. The company's strategic initiatives and market demand may have contributed to these revenue gains.
Profitability
The profit before tax (PBT) for Q4FY25 was ₹7.10 crores, showing an increase from ₹6.92 crores in the preceding quarter and ₹2.37 crores in Q4FY24. The QoQ growth for PBT stood at 2.6%, while the YoY growth was a remarkable 199.6%. Profit after tax (PAT) for Q4FY25 was ₹6.47 crores, up from ₹4.86 crores in Q3FY25 and ₹2.11 crores in Q4FY24, with a QoQ growth of 33.1% and a YoY growth of 206.6%. The tax expense for Q4FY25 was ₹0.63 crores, which decreased by 69.4% from the previous quarter, but saw a YoY increase of 152.0%. This decline in tax expenses from the previous quarter could have impacted the net profitability positively.
Operating Metrics
The analysis of operating metrics for SMS Lifesciences India Ltd reveals that total expenses for Q4FY25 were ₹85.25 crores, compared to ₹77.75 crores in Q3FY25 and ₹66.17 crores in Q4FY24. This constitutes a QoQ increase of 9.6% and a YoY increase of 28.8%, indicating an upward trend in operational costs. The earnings per share (EPS) for the quarter was ₹19.50, up from ₹18.10 in Q3FY25 and ₹5.70 in Q4FY24, reflecting a QoQ growth of 7.7% and a significant YoY growth of 242.1%. The substantial YoY increase in EPS suggests improved profitability for shareholders during the period.